Mabpharm Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Mabpharm.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 42.7% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now
Jun 14
More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%
Jan 24Mabpharm (HKG:2181) Is Making Moderate Use Of Debt
Oct 20Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation
Jan 18Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation
Oct 07Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation
Apr 28Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?
Mar 03We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate
Jan 27
Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?
Dec 09In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mabpharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 152 | -207 | 2 | 27 | N/A |
| 3/31/2024 | 119 | -208 | 20 | 42 | N/A |
| 12/31/2023 | 87 | -209 | 38 | 57 | N/A |
| 9/30/2023 | 79 | -202 | -38 | -11 | N/A |
| 6/30/2023 | 71 | -194 | -114 | -79 | N/A |
| 3/31/2023 | 64 | -202 | -148 | -68 | N/A |
| 12/31/2022 | 56 | -211 | -182 | -57 | N/A |
| 9/30/2022 | 43 | -237 | -235 | -80 | N/A |
| 6/30/2022 | 30 | -263 | -288 | -102 | N/A |
| 3/31/2022 | 57 | -278 | -318 | -151 | N/A |
| 12/31/2021 | 83 | -292 | -348 | -199 | N/A |
| 9/30/2021 | 82 | -284 | -342 | -185 | N/A |
| 6/30/2021 | 81 | -276 | -336 | -171 | N/A |
| 3/31/2021 | 41 | -230 | -340 | -159 | N/A |
| 12/31/2020 | N/A | -185 | -344 | -147 | N/A |
| 9/30/2020 | 5 | -163 | -340 | -147 | N/A |
| 6/30/2020 | 11 | -141 | -335 | -146 | N/A |
| 3/31/2020 | 12 | -172 | -292 | -141 | N/A |
| 12/31/2019 | 14 | -203 | -250 | -137 | N/A |
| 9/30/2019 | 16 | -208 | -195 | -113 | N/A |
| 6/30/2019 | 17 | -212 | -140 | -89 | N/A |
| 3/31/2019 | 21 | -169 | -146 | -76 | N/A |
| 12/31/2018 | 24 | -125 | -153 | -62 | N/A |
| 12/31/2017 | 5 | -31 | N/A | -65 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 2181's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 2181's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 2181's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 2181's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 2181's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2181's Return on Equity is forecast to be high in 3 years time